Printer Friendly

CAMBRIDGE NEUROSCIENCE INITIATES CLINICAL TRIALS OF CERESTAT FOR TRAUMATIC BRAIN INJURY; FIRST U.S. TBI TRIAL BEGINS AT HERMANN HOSPITAL

 CAMBRIDGE, Mass., July 27 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) today announced it has expanded and accelerated the clinical development of its lead compound Cerestat(tm) by initiating clinical trials in Traumatic Brain Injury (TBI) patients at two major neurological treatment centers in the United States and the United Kingdom.
 The first U.S. trial of the drug in TBI patients is now underway at Hermann Hospital, the primary teaching hospital for The University of Texas Medical School at Houston. A comparable Phase Ib trial of the drug has also been initiated at the University of Glasgow, Scotland. Both trials are designed to assess the safety and dosing regimen of the drug in brain injured patients, as well as to gain initial clinical experience in this target patient population, in preparation for Phase II trials planned for early 1994.
 According to Guy L. Clifton, M.D., chief of Neurosurgery at Hermann Hospital; chairman, Department of Neurosurgery at the University of Texas Medical School; and director of the Cerestat clinical trial program in Houston: "Traumatic Brain Injury is a leading killer and cause of disability in young adults. Tragically, there are no effective therapies to reduce the long-term neurological deficits that result from serious head injuries.
 "This drug comes out of one of the most promising areas of research in the field, and we believe it may have the ability to arrest the secondary biochemical cascade that occurs after the original trauma. This series of secondary metabolic events is believed to be the cause of additional long-term damage after the initial head injury."
 Dr. Clifton is an internationally known neurosurgeon and clinical investigator, recognized as an innovator in developing and testing new therapies to alleviate long-term neurologic deficits from head and spinal cord injuries. In 1992, Dr. Clifton received the National Head Injury Foundation Sheldon Berrol, M.D., Clinical Service Award. Hermann Hospital recently established a radiosurgery program with the Leksell Gamma Knife, one of only 13 such units in the country.
 Phase Ib clinical trials of the company's NMDA ion-channel blocker, Cerestat (CNS 1102), as a treatment for stroke patients began in February at six medical centers in New England. CNS management noted that promising clinical data emerging from these studies, as well as fundamental similarities regarding how brain damage develops in both stroke and TBI patients, led to the decision to test Cerestat in the TBI patient group.
 "We're delighted how rapidly we have been able to advance this drug. It was well tolerated in the initial tests in human volunteers. We have identified, and are already testing, doses that should provide therapeutic benefit in both stroke and traumatic brain injury. Cerestat clearly reaches the brain rapidly which is crucial to be of optimal benefit to patients," said Elkan Gamzu, Ph.D., president and chief operating officer of Cambridge NeuroScience. Phase II trials of Cerestat in stroke patients are also expected to start early next year.
 "As part of our expanded clinical development program, we have strengthened our clinical trial management team with the appointment of Heikki Hakkarainen, M.D., to the newly created position of Vice President, Clinical Studies. Dr. Hakkarainen joins us from CIBA-GEIGY Corporation where he most recently served as Executive Director of CNS Clinical Research, responsible for the design and supervision of all international stroke and head trauma clinical trials," added Dr. Gamzu.
 Cerestat acts to prevent nerve cell death and brain damage following stroke by preventing excessive entry of calcium into nerve cells. It is known that nerve cell death following a stroke or serious head injury is triggered by excessive glutamate released from damaged nerve terminals, which stimulates the massive entry of calcium into nerve cells.
 Approximately 500,000 people suffer TBI each year, accounting for the death of between 75,000 and 100,000 Americans annually. Of those who survive, approximately 70,000 to 90,000 will endure lifelong debilitating loss of function, and an additional 2,000 will exist in a persistent vegetative state. There are an additional 500,000 victims of stroke in the United States annually. No effective drug therapy is available to treat these patients, or to prevent the nerve damage that occurs subsequent to stroke and traumatic brain injury.
 Hermann Hospital, the first hospital in the Texas Medical Center, operates more than 650 beds and has a staff of 4,000 employees and 2,500 faculty, voluntary and house staff physicians. Hermann serves more than 11,000 patients and their families each month, and the hospital is a referral center for community hospitals throughout southeast Texas and western Louisiana. The Emergency Center at Hermann Hospital is a Level I trauma center, providing comprehensive 24-hour emergency and trauma services. The center also operates Hermann Life Flight, one of the largest and oldest emergency medical air transport services in the nation.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders such as diabetic peripheral neuropathy and multiple sclerosis.
 -0- 7/27/93
 /CONTACT: Elkan Gamzu, Ph.D., president and COO, Cambridge NeuroScience, 617-225-0600; Chris Taylor, account executive, Feinstein Partners Inc., 617-577-8110, for Cambridge NeuroScience; Elise Oppmann, media/marketing specialist, Hermann Hospital, 713-797-3370/
 (CNSI)


CO: Cambridge NeuroScience Inc., Hermann Hospital ST: Massachusetts IN: MTC SU:

DJ -- NE001 -- 6071 07/27/93 09:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:907
Previous Article:McDONALD & CO. NAMES PRESIDENT SUMMERS TO SUCCEED CHAIRMAN O'DONNELL AS CEO
Next Article:ALDUS ACQUIRES DIGITAL-VIDEO SOFTWARE COMPANY
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE EXPANDS CLINICAL STUDIES OF CERESTAT(TM) IN STROKE PATIENTS
ADDITIONAL SAFETY RESULTS PRESENTED FOR CAMBRIDGE NEUROSCIENCE'S CERESTAT(TM)
CAMBRIDGE NEUROSCIENCE BEGINS MULTINATIONAL DOSE-FINDING STUDY OF CERESTAT(TM) IN STROKE PATIENTS
CAMBRIDGE NEUROSCIENCE PRESENTS CONFIRMATORY CLINICAL RESULTS FOR CERESTAT(R) IN BRAIN INJURY PATIENTS
CAMBRIDGE NEUROSCIENCE COMPLETES ENROLLMENT FOR PHASE II DOSE RESPONSE STUDY OF CERESTAT(R) IN STROKE PATIENTS
CLINICAL DATA SUPPORTING CERESTAT(R) IN STROKE PATIENTS REPORTED AT AMERICAN HEART ASSOCIATION MEETING
CAMBRIDGE NEUROSCIENCE INITIATES PHASE III STUDY OF CERESTAT(R) IN PATIENTS WITH TRAUMATIC BRAIN INJURY
CAMBRIDGE NEUROSCIENCE CERESTAT(R) DATA IN STROKE PATIENTS REPORTED AT AMERICAN ACADEMY OF NEUROLOGY
CAMBRIDGE NEUROSCIENCE AND BOEHRINGER INGELHEIM INITIATE PIVOTAL TRIAL OF CERESTAT IN STROKE
Cambridge NeuroScience Discontinues Traumatic Brain Injury Trial

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters